Paper41018201
Therapeutic advances in type 1 myotonic dystrophy complicated with type 2 diabetes mellitus.
Luo L and 5 others. Front Neurol, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Therapeutic advances in type 1 myotonic dystrophy complicated with type 2 diabetes mellitus. Papers, record 41018201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41018201
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Therapeutic advances in type 1 myotonic dystrophy complicated with type 2 diabetes mellitus.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References167
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18834994 | A cross-sectional study for glucose intolerance of myotonic dystrophy. | J Neurol Sci | 2009 | https://conductscience.org/library/papers/18834994 | PubMed |
| 2 | 24126227 | The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. | Endocr Pract | 2013 | https://conductscience.org/library/papers/24126227 | PubMed |
| 3 | 29289451 | Mitochondrial dysfunction in myotonic dystrophy type 1. | Neuromuscul Disord | 2018 | https://conductscience.org/library/papers/29289451 | PubMed |
| 4 | 29404559 | Development and Validation of a New Scoring System to Predict Survival in Patients With Myotonic Dystrophy Type 1. | JAMA Neurol | 2018 | https://conductscience.org/library/papers/29404559 | PubMed |
| 5 | 31479430 | Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice. | J Clin Invest | 2019 | https://conductscience.org/library/papers/31479430 | PubMed |
| 6 | 32637445 | Unexpected Mutations by CRISPR-Cas9 CTG Repeat Excision in Myotonic Dystrophy and Use of CRISPR Interference as an Alternative Approach. | Mol Ther Methods Clin Dev | 2020 | https://conductscience.org/library/papers/32637445 | PubMed |
| 7 | 34172001 | Late-onset neuromuscular disorders in the differential diagnosis of sarcopenia. | BMC Neurol | 2021 | https://conductscience.org/library/papers/34172001 | PubMed |
| 8 | 30182324 | Cancer incidence among Finnish people with type 2 diabetes during 1989-2014. | Eur J Epidemiol | 2019 | https://conductscience.org/library/papers/30182324 | PubMed |
| 9 | 36002078 | Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities. | Pharmacol Ther | 2022 | https://conductscience.org/library/papers/36002078 | PubMed |
| 10 | 28129118 | CRISPR/Cas9-Induced (CTG⋅CAG)n Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing. | Mol Ther | 2017 | https://conductscience.org/library/papers/28129118 | PubMed |
| 11 | 11528389 | Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. | Nat Genet | 2001 | https://conductscience.org/library/papers/11528389 | PubMed |
| 12 | 21812507 | Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. | Drugs | 2011 | https://conductscience.org/library/papers/21812507 | PubMed |
| 13 | 25753670 | Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy. | Nucleic Acids Res | 2015 | https://conductscience.org/library/papers/25753670 | PubMed |
| 14 | 16864839 | Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2). | Neurology | 2006 | https://conductscience.org/library/papers/16864839 | PubMed |
| 15 | 32310829 | Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin. | Aging (Albany NY) | 2020 | https://conductscience.org/library/papers/32310829 | PubMed |
| 16 | 21748485 | Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. | Diabetologia | 2011 | https://conductscience.org/library/papers/21748485 | PubMed |
| 17 | 25121518 | Myotonic dystrophy: diagnosis, management and new therapies. | Curr Opin Neurol | 2014 | https://conductscience.org/library/papers/25121518 | PubMed |
| 18 | 521833 | Myotonic dystrophy associated with thyroid disease. | J Neurol Sci | 1979 | https://conductscience.org/library/papers/521833 | PubMed |
| 19 | 30053870 | Dissimilar impact of type 2 diabetes on cardiovascular outcomes according to age categories: a nationwide population study from Hungary. | Cardiovasc Diabetol | 2018 | https://conductscience.org/library/papers/30053870 | PubMed |
| 20 | 31045770 | Clinical implication of maximal voluntary ventilation in myotonic muscular dystrophy. | Medicine (Baltimore) | 2019 | https://conductscience.org/library/papers/31045770 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41018201
GET https://conductscience.org/api/papers/v1/41018201/references?page=2